ArticleKidney diseases (Basel, Switzerland)
Post-Transplant Recurrence of Focal Segmental Glomerulosclerosis: Circulating Factors, Molecular Biomarkers, and Treatments.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Focal segmental glomerulosclerosis (FSGS), a clinicopathological condition characterized by nephrotic-range proteinuria and presenting microscopically as focal segmental sclerosis of the glomerulus, often progresses to end-stage renal disease. Patients with primary FSGS who undergo kidney transplantation often experience recurrence, leading to graft function loss and ultimately a shortened life span. However, the pathogenesis about post-transplant recurrence of FSGS remains unclear. Summary: The mainstream hypothesis is the circulating factor, which mediates podocyte injury. Although a unified gold standard circulating factor has yet to be established, several candidate circulating factors have been proposed, including soluble urokinase plasminogen activator receptor (suPAR), the CD40-CD40L axis, cardiotrophin-like cytokine factor 1 (CLCF-1), apolipoprotein A-Ib (ApoA-Ib), and anti-nephrin antibody. These candidates have demonstrated associations with recurrent FSGS in clinical or basic research, but each has certain limitations. Additionally, advancements in renal biopsy, podocyte molecular signaling targets, and microRNAs provide support for the development of novel molecular biomarkers. Currently, there is no unified guideline for the treatment of post-transplant recurrent FSGS. Common therapeutic options include plasma exchange, calcineurin inhibitors, corticosteroids, and rituximab. Key Messages: This article summarizes the latest research advancements of circulating factors in post-transplant recurrence of FSGS and also highlights recent discoveries in potential molecular biomarkers and therapeutic approaches. Post-transplant recurrence of FSGS is a rare and complex heterogeneous disease that seriously affects the health of patients. The review aimed to provide valuable and up-to-date information support for researchers in this field and give potential research perspectives in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.